Pfizer's COVID vaccine edges past Moderna's efficacy rate, to seek emergency approval soon

Days after reporting over 90 per cent efficacy, Pfizer and BioNTech on Wednesday anunced that its COVID-19 vaccine candidate - BNT162b2 - has met all of primary efficacy endpoints. Concluding from analysis, biotech firm stated that its vaccine candidate has shown an efficacy rate of 95 per cent in participants with and without prior COVID infection. However, efficacy reduced by a per cent in ults over of 65 years. analysis by Pfizer and BioNTech is based on 170 participants. 

companies have also anunced that it has achieved safety milestone required by U.S. Food and Drug ministration (FDA) for Emergency Use Authorization (EUA). Based on safety and efficacy data collected, firms intend to submit a request within days to FDA for a EUA. anuncement comes just two days after Moderna reported that its vaccine candidate h shown nearly 95% efficacy rate. 

“ study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at speed of science to compile all data collected thus far and share with regulators around world,” said Dr Albert Bourla, Pfizer Chairman and CEO. “With hundreds of thousands of people around globe infected every day, we urgently need to get a safe and effective vaccine to world,” he ded. 

RE | It's Moderna Vs Pfizer As US Covid Vaccines Score 90%+ Trials Success; Which Has Edge? 

Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of vaccine candidate as of vember 13, 2020. Approximately 42 per cent of global participants and 30 per cent of U.S. participants have racially and ethnically diverse backgrounds, and 41 per cent of global and 45 per cent of U.S. participants are 56-85 years of . 

Moderna reports 94.5 per cent efficacy 

Moderna on Monday reported that its COVID-19 vaccine candidate has proven to be 94.5 per cent effective. biotechlogy company has informed that it intends to submit COVID-19 vaccine candidate for an Emergency Use Authorization (EUA) with United States' Food & Drug ministration (FDA). analysis released by Moderna which has reported 94.5 per cent efficacy of COVID-19 vaccine was based on results of more than 30,000 participants in US.

RE | Moderna's COVID Vaccine Reports 94.5% Efficacy, To Seek US FDA's Emergency Authorization